Clinical Trials · NCT03553602

HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer

TerminatedPhase 1/Phase 2Gonadorelin (Prohibited)
Phase
Phase 1/Phase 2
Recruitment status
Terminated
Sponsor
Loyola University
Enrollment
3
Start date
Dec 2017
Locations
1 site, United States
Primary endpoint
Genitourinary Toxicity
View Gonadorelin compound reference